Considering the capacity of b-AP15 to specifically enhance the expression of TRAIL-R2 on tumor cells, we suggest the combination of b-AP15 and cellular therapy with activated NK- and T-cells as a potential therapeutic strategy for cancer patients. Here, TNFRSF10B is linked to cancer.